EUVIMEDEUVIMED entdecken
Crossref

Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study

Tarik Salman, Seher Nazli Kazaz, Umut Varol, Utku Oflazoglu, Ilkay Tugba Unek, Yuksel Kucukzeybek, Ahmet Alacacioglu, Elif Atag, Huseyin Salih Semiz, Hakan Cengiz, Ilhan Oztop, Mustafa Oktay Tarhan

Chemotherapy · 2016 · 61 (6) · 281-286

DOI: 10.1159/000445045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 13.04.2016. Verfasst von Tarik Salman und 11 weiteren Autor:innen. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several studies evaluating the prognostic factors of gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs) have been published. The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been accepted as prognostic factors for cancer patients. Materials and Methods: This study included 132 patients diagnosed with GEP-NETs. Peripheral blood samples were collected before the pretreatment period.

Results

NLR and PLR were increased as the grade increased in NETs. The embryonic origin analysis revealed higher NLR and PLR rates in NETs of foregut origin. NLR and PLR were also higher in pancreatic NET patients compared to the gastroenteric NET patients. Analysis of NETs by TNM indicated that an advanced stage was accompanied by significantly higher NLR and PLR. We found a strong negative correlation between progression-free survival and NLR and PLR.

Conclusion

The study verified that NLR and PLR are simple laboratory findings that can be used to identify NETs with a worse outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Age FactorsAgedAged, 80 and overArea Under CurveBlood Cell CountBlood PlateletsDisease-Free SurvivalFemaleHumansLymphocytesMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingNeuroendocrine TumorsNeutrophilsPrognosisROC CurveSex Factors

Zitieren

APA

Salman, T., Kazaz, S. N., Varol, U., Oflazoglu, U., Unek, I. T., Kucukzeybek, Y., Alacacioglu, A., Atag, E., Semiz, H. S., Cengiz, H., Oztop, I., & Tarhan, M. O. (2016). Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study. Chemotherapy, 61(6), 281-286. https://doi.org/10.1159/000445045

Vancouver

Salman T, Kazaz SN, Varol U, Oflazoglu U, Unek IT, Kucukzeybek Y, et al. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study. Chemotherapy. 2016;61(6):281-286. doi:10.1159/000445045

BibTeX
@article{Salman2016,
  author = {Salman, Tarik and Kazaz, Seher Nazli and Varol, Umut and Oflazoglu, Utku and Unek, Ilkay Tugba and Kucukzeybek, Yuksel and Alacacioglu, Ahmet and Atag, Elif and Semiz, Huseyin Salih and Cengiz, Hakan and Oztop, Ilhan and Tarhan, Mustafa Oktay},
  title = {Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study},
  journal = {Chemotherapy},
  year = {2016},
  volume = {61},
  number = {6},
  pages = {281--286},
  doi = {10.1159/000445045}
}
Kostenlos starten →